logo

Hutchison China Meditech Ltd (HCM)



Trade HCM now with
  Date
  Headline
8/8/2022 6:38:50 AM HUTCHMED, AstraZeneca Announce Preliminary Results From SAVANNAH Phase II Trial
8/8/2022 1:08:59 AM HUTCHMED Says Fruquintinib Global Phase III FRESCO-2 Study Meets Primary Endpoint In Metastatic Colorectal Cancer
7/15/2022 4:58:16 AM HUTCHMED Initiates Phase I Trial Of Anti-CD47 Monoclonal Antibody HMPL-A83 In Advanced Malignant Neoplasms
7/6/2022 1:01:52 AM Inmagene And HUTCHMED Announce First Participants In Global Phase I Trial Of IMG-007
5/15/2022 8:42:34 PM Inmagene Gets FDA IND Clearance For Third Generation BTK Inhibitor Targeting Immunological Diseases
5/2/2022 6:24:44 AM HUTCHMED Gets Complete Response Letter From FDA For Surufatinib For Advanced Neuroendocrine Tumors
3/7/2022 2:20:32 AM HUTCHMED Gets $15 Mln Milestone From AstraZeneca For Initiating Start-up Activities For Phase III Study Of ORPATHYS
3/3/2022 7:44:27 AM HUTCHMED Names Weiguo Su CEO To Succeed Christian Hogg
3/1/2022 4:10:08 AM HUTCHMED Gets Approval To Commercialize ELUNATE In Macau
1/12/2022 6:08:30 AM HUTCHMED Gets Breakthrough Therapy Designation In China For HMPL-523 For Immune Thrombocytopenia
11/1/2021 1:10:30 AM HUTCHMED, AstraZeneca Begins SAMETA Phase III Trial Of Savolitinib With PD-L1 Inhibitor IMFINZI